Dr. Park on Updates With CAR T Cells in ALL

Video

Jae H. Park, MD, discusses encouraging data with CAR T-cell therapy in acute lymphoblastic leukemia.

Jae H. Park, MD, attending physician, Leukemia Service and Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses encouraging data with CAR T-cell therapy in acute lymphoblastic leukemia (ALL).

Initial data with CAR T-cell therapy showed a complete response rate of approximately 80% in pediatric and adult patients with relapsed/refractory ALL, says Park. Although approximately 40% of patients will relapse early, some patients can experience durable responses lasting 3 to 5 years.

Ongoing research is evaluating which patients will benefit the most from this strategy, explains Park. The goal is to minimize toxicity and improve remission durations while retaining efficacy. To date, patients with lower disease burden appear to derive the greatest benefit from CAR T-cell therapy.

Ongoing trials are exploring additional targets with the goal of minimizing, and ultimately eliminating, toxicity, concludes Park.

Recent Videos
Lucas Harrington, PhD, the cofounder and chief scientific officer of Mammoth Biosciences
Miloš Miljković, MD, on mRNA-CAR-T Descartes-08's Potential for Treating Myasthenia Gravis
Manali Kamdar, MD, on Liso-Cel's Ongoing Benefit in the Treatment Lanscape for LBCL
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
David Dimmock, MBBS, on AI-Guided ASO Development for Ultra-Rare Diseases
Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment
Subhash Tripathi, PhD, on Generating In Vivo CARs With A2-CAR-CISC EngTreg Cells
Luke Roberts, MBBS, PhD, on Challenges in Developing Gene Therapy for Heart Failure
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
© 2024 MJH Life Sciences

All rights reserved.